**9. References**


Peroxisome Proliferator-Activated

*Immunol* 2002;2:748-59.

*Cardiol* 2008;51:49-55.

1992;68:879-87.

2008;368:402-7.

2008;5:319-35.

alpha. *Molecular Endocrinology* 2002;16:1029-39.

strategies. *J Exp Med* 2001;193:827-38.

Receptor β/δ (PPARβ/δ) as a Potential Therapeutic Target for Dyslipidemia 229

Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. *Nat Rev* 

deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein

Delerive P, De Bosscher K, Vanden Berghe W, Fruchart JC, Haegeman G, Staels B. DNA

Delerive P, De BK, Besnard S et al. Peroxisome proliferator-activated receptor alpha

Desreumaux P, Dubuquoy L, Nutten S et al. Attenuation of colon inflammation through

Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal

Du J, Guan T, Zhang H, Xia Y, Liu F, Zhang Y. Inhibitory crosstalk between ERK and AMPK

Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to

Finck BN, Gropler MC, Chen Z et al. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. *Cell Metab* 2006;4:199-210.

Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and

Fruchart JC, Sacks FM, Hermans MP et al. The Residual Risk Reduction Initiative: a call to

Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W. The peroxisome

Griffin ME, Marcucci MJ, Cline GW et al. Free fatty acid-induced insulin resistance is

Grundy SM. Atherogenic dyslipidemia: lipoprotein abnormalities and implications for

Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet* 2005;365:1415-28. Estall JL, Kahn M, Cooper MP et al. Sensitivity of lipid metabolism and insulin signaling to

coactivator-1alpha expression. *Diabetes* 2009;58:1499-508.

delta. *Proc Natl Acad Sci U S A* 1997;94:4312-17.

diabetic controls. *Atherosclerosis* 2005;183:336-41.

signaling cascade. *Diabetes* 1999;48:1270-1274.

therapy. *Am J Cardiol* 1995;75:45B-52B.

cholesterol in patients with low low-density lipoprotein cholesterol. *J Am Coll* 

binding-independent induction of I kappa B alpha gene transcription by PPAR

negatively regulates the vascular inflammatory gene response by negative crosstalk with transcription factors NF-kappaB and AP-1. *J Biol Chem* 1999;274:32048-54.

activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic

beta-oxidation pathway by a novel family of nuclear hormone receptors. *Cell*

in the growth and proliferation of cardiac fibroblasts. *Biochem Biophys Res Commun*

genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma

physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. *Prog Lipid Res* 2006;45:120-159.

eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and

action to reduce residual vascular risk in dyslipidaemic patient. *Diab Vasc Dis Res*

proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-

associated with activation of protein kinase C theta and alterations in the insulin


Boden G, Jadali F, White J et al. Effects of fat on insulin-stimulated carbohydrate metabolism

Bou KM, Sundaram M, Zhang HY et al. The level and compartmentalization of

Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome

Bruce CR, Hoy AJ, Turner N et al. Overexpression of carnitine palmitoyltransferase-1 in

Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin

Canto C, Gerhart-Hines Z, Feige JN et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. *Nature* 2009;458:1056-60. Castelli WP. Epidemiology of triglycerides: a view from Framingham. *Am J Cardiol*

Cederberg H, Saukkonen T, Laakso M et al. Postchallenge glucose, A1C, and fasting glucose

Chakravarthy MV, Lodhi IJ, Yin L et al. Identification of a physiologically relevant

Chakravarthy MV, Pan Z, Zhu Y et al. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. *Cell Metab* 2005;1:309-22. Chan DC, Watts GF. Dyslipidaemia in the metabolic syndrome and type 2 diabetes:

Chawla A, Lee CH, Barak Y et al. PPARdelta is a very low-density lipoprotein sensor in

Chen Z, Gropler MC, Norris J, Lawrence JC, Jr., Harris TE, Finck BN. Alterations in hepatic

Chung S, Lapoint K, Martinez K, Kennedy A, Boysen SM, McIntosh MK. Preadipocytes

Coll T, Barroso E, Alvarez-Guardia D et al. The Role of Peroxisome Proliferator-Activated

Coll T, Alvarez-Guardia D, Barroso E et al. Activation of peroxisome proliferator-activated

Cortright RN, Azevedo JL, Zhou Q et al. Protein kinase C modulates insulin action in

endogenous ligand for PPARalpha in liver. *Cell* 2009;138:476-88.

macrophages. *Proc Natl Acad Sci U S A* 2003;100:1268-73.

secretion. *Arterioscler Thromb Vasc Biol* 2008;28:1738-44.

as predictors of type 2 diabetes and cardiovascular disease: a 10-year prospective

pathogenesis, priorities, pharmacotherapies. *Expert Opin Pharmacother* 2011;12:13-

metabolism in fld mice reveal a role for lipin 1 in regulating VLDL-triacylglyceride

mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes. *Endocrinology*

Receptor beta/delta on the Inflammatory Basis of Metabolic Disease. *PPAR Res*

receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells. *Endocrinology*

human skeletal muscle. *American Journal of Physiology-Endocrinology and Metabolism*

and -gamma in the adult rat. *Endocrinology* 1996;137:354-66.

diet-induced insulin resistance. *Diabetes* 2009;58:550-558.

phosphatidate phosphatase-1 (lipin-1) control the assembly and secretion of hepatic

proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta,

skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat

in normal men. *J Clin Invest* 1991;88:960-966.

VLDL. *J Lipid Res* 2009;50:47-58.

resistance. *Diabetes* 2007;56:1761-72.

cohort study. *Diabetes Care* 2010;33:2077-83.

1992;70:3H-9H.

2006;147:5340-5351.

2010b;151:1560-1569.

2000;278:E553-E562.

2010a;2010.

30.


Peroxisome Proliferator-Activated

1994;91:7355-59.

2006b;340:291-95.

*Lipidol* 1997;8:146-53.

707.

muscle. *J Biol Chem* 2007;282:19313-20.

kinase activation. *J Biol Chem* 2008;283:27628-35.

in db/db mice. *FEBS Lett* 2000;473:333-36.

Study (IRAS). *Diabetes Care* 2010;33:2104-9.

*Vasc Health Risk Manag* 2006;2:285-302.

transcription via Sp1. *Endocr J* 2010;57:403-13.

*Pharmacol Ther* 2010;87:407-16.

*A* 2001;98:5306-11.

sensitivity. *Proc Natl Acad Sci U S A* 2006a;103:3444-49.

Receptor β/δ (PPARβ/δ) as a Potential Therapeutic Target for Dyslipidemia 231

Kliewer SA, Forman BM, Blumberg B et al. Differential expression and activation of a family

Kramer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A. Role of AMP kinase

Krey G, Braissant O, L'Horset F et al. Fatty acids, eicosanoids, and hypolipidemic agents

Lan F, Cacicedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status,

Lee CH, Olson P, Hevener A et al. PPARdelta regulates glucose metabolism and insulin

Lee WJ, Kim M, Park HS et al. AMPK activation increases fatty acid oxidation in skeletal

Leibowitz MD, Fievet C, Hennuyer N et al. Activation of PPARdelta alters lipid metabolism

Lewis GF. Fatty acid regulation of very low density lipoprotein production. *Curr Opin* 

Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor gamma-dependent

Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM. A1C between

Mathieu P, Lemieux I, Despres JP. Obesity, inflammation, and cardiovascular risk. *Clin* 

Mathieu P, Pibarot P, Despres JP. Metabolic syndrome: the danger signal in atherosclerosis.

Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride

Nguyen MT, Favelyukis S, Nguyen AK et al. A subpopulation of macrophages infiltrates

Oliver WR, Jr., Shenk JL, Snaith MR et al. A selective peroxisome proliferator-activated

Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. *Int J Obes Relat Metab Disord* 2003;27 Suppl 3:S6-11.

the PROVE IT-TIMI 22 trial. *J Am Coll Cardiol* 2008;51:724-30.

dependent receptor ligand assay. *Mol Endocrinol* 1997;11:779-91.

of murine peroxisome proliferator-activated receptors. *Proc Natl Acad Sci U S A*

and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal

identified as ligands of peroxisome proliferator-activated receptors by coactivator-

cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein

muscle by activating PPARalpha and PGC-1. *Biochem Biophys Res Commun*

repression of the inducible nitric oxide synthase gene. *Mol Cell Biol* 2000;20:4699-

5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis

levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in

hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. *J Biol Chem* 2007;282:35279-92. Okazaki M, Iwasaki Y, Nishiyama M et al. PPARbeta/delta regulates the human SIRT1 gene

receptor delta agonist promotes reverse cholesterol transport. *Proc Natl Acad Sci U S* 


Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic

Gustafson B, Gogg S, Hedjazifar S, Jenndahl L, Hammarstedt A, Smith U. Inflammation and

Haber EP, Hirabara SM, Gomes AD, Curi R, Carpinelli AR, Carvalho CR. Palmitate

Higashida K, Higuchi M, Terada S. Potential role of lipin-1 in exercise-induced mitochondrial biogenesis. *Biochem Biophys Res Commun* 2008;374:587-91. Hirabara SM, Curi R, Maechler P. Saturated fatty acid-induced insulin resistance is

Hirabara SM, Silveira LR, Abdulkader F, Carvalho CR, Procopio J, Curi R. Time-dependent effects of fatty acids on skeletal muscle metabolism. *J Cell Physiol* 2007;210:7-15. Hondares E, Pineda-Torra I, Iglesias R, Staels B, Villarroya F, Giralt M. PPARdelta, but not

Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated

Itani SI, Zhou Q, Pories WJ, MacDonald KG, Dohm GL. Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. *Diabetes* 2000;49:1353-58. Jeninga EH, Schoonjans K, Auwerx J. Reversible acetylation of PGC-1: connecting energy sensors and effectors to guarantee metabolic flexibility. *Oncogene* 2010;29:4617-24. Johnson TE, Holloway MK, Vogel R et al. Structural requirements and cell-type specificity

Kamei Y, Xu L, Heinzel T et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. *Cell* 1996;85:403-14. Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery

Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis

Kersten S. Peroxisome proliferator activated receptors and lipoprotein metabolism. *PPAR* 

Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. *Nature*

Kim JK, Kim YJ, Fillmore JJ et al. Prevention of fat-induced insulin resistance by salicylate.

induced insulin resistance. *Science* 1996;271:665-68.

signaling through IRS-1 phosphorylation. *Biochimie* 2005;87:99-109.

*Metab* 2009.

*Lett* 2003;544:185-88.

2010;222:187-94.

*Commun* 2007;354:1021-27.

*Biochem Mol Biol* 1997;63:1-8.

*Res* 2008;2008:132960.

2000;405:421-24.

disease. *Am J Cardiol* 1983;52:9B-12B.

*Physiol Endocrinol Metab* 2001;280:E745-E751.

*Journal of Clinical Investigation* 2001;108:437-46.

syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. *Cardiol Rev* 2005;13:322-27. Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin

impaired adipogenesis in hypertrophic obesity in man. *Am J Physiol Endocrinol* 

modulates the early steps of insulin signalling pathway in pancreatic islets. *FEBS* 

associated with mitochondrial dysfunction in skeletal muscle cells. *J Cell Physiol*

PPARalpha, activates PGC-1alpha gene transcription in muscle. *Biochem Biophys Res* 

inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-

for ligand activation of peroxisome proliferator-activated receptors. *J Steroid* 

factor and interleukin-6 expression in human obesity and insulin resistance. *Am J* 


Peroxisome Proliferator-Activated

2006;116:1793-801.

muscle. *J Cell Physiol* 2008;217:1-12.

*Endocrinol* 2010;204:93-104.

*Endocrinol* 2000;14:733-40.

2003;46:733-49.

2005;46:526-34.

2005;46:1009-16.

19.

in men. *Arterioscler Thromb Vasc Biol* 2003;23:637-43.

biological activity. *Bioorg Med Chem Lett* 2003;13:1517-21.

to inflammation. *Genes Dev* 2001;15:3263-77.

(UKPDS: 23). *BMJ* 1998;316:823-28.

by PPARdelta. *PLoS Biol* 2004;2:e294.

Receptor β/δ (PPARβ/δ) as a Potential Therapeutic Target for Dyslipidemia 233

Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially

Shepherd J, Betteridge J, Van GL. Nicotinic acid in the management of dyslipidaemia

Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and

Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *J Clin Invest*

Silveira LR, Fiamoncini J, Hirabara SM et al. Updating the effects of fatty acids on skeletal

Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E. Evidence that

Sugden MC, Caton PW, Holness MJ. PPAR control: it's SIRTainly as easy as PGC. *J* 

Sznaidman ML, Haffner CD, Maloney PR et al. Novel selective small molecule agonists for

Takada I, Yu RT, Xu HE et al. Alteration of a single amino acid in peroxisome proliferator-

Tan NS, Michalik L, Noy N et al. Critical roles of PPAR beta/delta in keratinocyte response

Tanaka T, Yamamoto J, Iwasaki S et al. Activation of peroxisome proliferator-activated

Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. *Diabetologia*

Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin

van d, V, Kruit JK, Havinga R et al. Reduced cholesterol absorption upon PPARdelta

Wallace JM, Schwarz M, Coward P et al. Effects of peroxisome proliferator-activated

Wang YX, Zhang CL, Yu RT et al. Regulation of muscle fiber type and running endurance

Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. *J Clin Invest* 2005;115:1111-

Xu HE, Lambert MH, Montana VG et al. Molecular recognition of fatty acids by peroxisome

proliferator-activated receptors. *Mol Cell* 1999;3:397-403.

metabolic syndrome. *Proc Natl Acad Sci U S A* 2003;100:15924-29.

peroxisome proliferator-activated receptor delta influences cholesterol metabolism

peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and

activated receptor-alpha (PPAR alpha) generates a PPAR delta phenotype. *Mol* 

receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates

dependent diabetes mellitus: United Kingdom Prospective Diabetes Study

activation coincides with decreased intestinal expression of NPC1L1. *J Lipid Res*

receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys. *J Lipid Res*

European Consensus Panel. *Curr Med Res Opin* 2005;21:665-82.

fatty acid-induced insulin resistance. *J Clin Invest* 2006;116:3015-25.

below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. *Diabetes Care* 2006;29:1220-1226.

associated with diabetes and metabolic syndrome: a position paper developed by a


Peters JM, Lee SS, Li W et al. Growth, adipose, brain, and skin alterations resulting from

Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA* 2001;286:327-34. Reznick RM, Shulman GI. The role of AMP-activated protein kinase in mitochondrial

Riserus U, Sprecher D, Johnson T et al. Activation of peroxisome proliferator-activated

Robitaille J, Gaudet D, Perusse L, Vohl MC. Features of the metabolic syndrome are

Roden M, Perseghin G, Petersen KF et al. The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans. *J Clin Invest* 1996;97:642-48.

Rodriguez-Calvo R, Serrano L, Coll T et al. Activation of peroxisome proliferator-activated

Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-

Ruderman NB, Xu XJ, Nelson L et al. AMPK and SIRT1: a long-standing partnership? *Am J* 

Sanderson LM, Boekschoten MV, Desvergne B, Muller M, Kersten S. Transcriptional

Schrauwen P, Schrauwen-Hinderling V, Hoeks J, Hesselink MK. Mitochondrial dysfunction

Sebastian D, Herrero L, Serra D, Asins G, Hegardt FG. CPT I overexpression protects L6E9

Serrano-Marco L, Rodriguez-Calvo R, El K, I et al. Activation of Peroxisome Proliferator-

Shaw N, Elholm M, Noy N. Retinoic acid is a high affinity selective ligand for the

of gene expression in mouse liver. *Physiol Genomics* 2010;41:42-52.

and lipotoxicity. *Biochim Biophys Acta* 2010;1801:266-71.

Stimulated Adipocytes. *Diabetes* 2011;60:1990-1999.

beta(delta). *Mol Cell Biol* 2000;20:5119-28.

syndrome X. *Diabetologia* 1997;40:1286-92.

related kinase 1/2. *Diabetes* 2008;57:2149-57.

*Physiol Endocrinol Metab* 2010;298:E751-E760.

biogenesis. *J Physiol* 2006;574:33-39.

men. *Diabetes* 2008;57:332-39.

*Obes (Lond)* 2007;31:411-17.

*Metab* 2007;292:E677-E686.

2002;90:89-94.

92.

targeted disruption of the mouse peroxisome proliferator-activated receptor

system: association of acute-phase reactants and interleukin-6 with metabolic

receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese

modulated by an interaction between the peroxisome proliferator-activated receptor-delta -87T>C polymorphism and dietary fat in French-Canadians. *Int J* 

receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-

density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. *Am J Cardiol*

profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation

muscle cells from fatty acid-induced insulin resistance. *Am J Physiol Endocrinol* 

Activated Receptor-{beta}/-{delta} (PPAR-{beta}/-{delta}) Ameliorates Insulin Signaling and Reduces SOCS3 Levels by Inhibiting STAT3 in Interleukin-6-

peroxisome proliferator-activated receptor beta/delta. *J Biol Chem* 2003;278:41589-


**12** 

*Spain* 

**Liver Glucokinase and Lipid Metabolism** 

Control of energy metabolism is crucial for optimal functioning of organs and tissues. Amongst all nutrients, glucose is the principal energy source for most cells and, therefore, minimum blood glucose levels must be guaranteed. Alterations in glycaemia can lead to hyperglycaemic states (producing protein glycosylation and toxicity in glucose-sensitive cells) or hypoglycaemic states (that can affect brain function), both harmful. Therefore, mechanisms must exist to keep glycaemia in a narrow physiological range (4-8 mM) independently of the nutritional state. To achieve control of blood glucose levels, our body has a complex, interorgan signaling system using nutrients (glucose, lipids, amino acids), hormones (insulin, glucagon, ghrelin, etc.) and the autonomic nervous system. In response to these signals, organs and tissues (mainly intestine, endocrine pancreas, liver, skeletal muscle, adipose tissue, brain and adrenal glands) adapt their function to energetic

The liver plays a pivotal role in the maintenance of glucose homeostasis by continuously adapting its metabolism to energetic needs. In the fed state, when blood glucose levels are high and there is insulin, liver takes-up part glucose to replenish glycogen stores. Besides, when glucose stores are full, the liver has the capacity to synthesize lipids *de novo* from glucose for-long term energy storage. Lipids are packaged in very low-density lipoprotein (VLDL) particles and then transported to the adipose tissue. Conversely during starvation, when glycaemia falls and glucagon increases, the liver produces glucose to maintain circulating glucose levels by breaking down glycogen stores or by synthesizing glucose de novo through gluconeogenesis. Gluconeogenesis, as an energy-consuming pathway, is

From this introduction on the regulation of glucose homeostasis, one can appreciate the close relation that exists between carbohydrate metabolism and lipid metabolism in the liver. Therefore, alterations in hepatic carbohydrate metabolic pathways may directly affect hepatic and/or blood lipid levels. Particularly, this chapter will focus on evaluating the incidence of glucokinase (GK) –the first enzyme of the glycolytic pathway in the liveron lipidemia and on hepatic lipid content. But first, an introductory overview of the physiology behind the first-pass metabolism of dietary glucose in the liver will be

linked to β-oxidation of fatty acids (fuel supplier pathway).

**1. Introduction** 

requirements.

presented.

Anna Vidal-Alabró, Andrés Méndez-Lucas, Jana Semakova,

Alícia G. Gómez-Valadés and Jose C. Perales

*Department of Physiological Sciences II, University of Barcelona, Barcelona,* 

